Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types

Abstract Immune checkpoint inhibitors have demonstrated significant survival benefits in treating many types of cancers. However, their immune-related adverse events (irAEs) have not been systematically evaluated across cancer types in large-scale real-world populations. To address this gap, we cond...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Feicheng Wang, Shihao Yang, Nathan Palmer, Kathe Fox, Isaac S. Kohane, Katherine P. Liao, Kun-Hsing Yu, S. C. Kou
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c77b8b4112604201bb4324a10379722d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c77b8b4112604201bb4324a10379722d
record_format	dspace
spelling	oai:doaj.org-article:c77b8b4112604201bb4324a10379722d2021-12-02T19:13:54ZReal-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types10.1038/s41698-021-00223-x2397-768Xhttps://doaj.org/article/c77b8b4112604201bb4324a10379722d2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41698-021-00223-xhttps://doaj.org/toc/2397-768XAbstract Immune checkpoint inhibitors have demonstrated significant survival benefits in treating many types of cancers. However, their immune-related adverse events (irAEs) have not been systematically evaluated across cancer types in large-scale real-world populations. To address this gap, we conducted real-world data analyses using nationwide insurance claims data with 85.97 million enrollees across 8 years. We identified a significantly increased risk of developing irAEs among patients receiving immunotherapy agents in all seven cancer types commonly treated with immune checkpoint inhibitors. By six months after treatment initialization, those receiving immunotherapy were 1.50–4.00 times (95% CI, lower bound from 1.15 to 2.16, upper bound from 1.69 to 20.36) more likely to develop irAEs in the first 6 months of treatment, compared to matched chemotherapy or targeted therapy groups, with a total of 92,858 patients. The risk of developing irAEs among patients using nivolumab is higher compared to those using pembrolizumab. These results confirmed the need for clinicians to assess irAEs among cancer patients undergoing immunotherapy as part of management. Our methods are extensible to characterizing the effectiveness and adverse effects of novel treatments in large populations in an efficient and economical fashion.Feicheng WangShihao YangNathan PalmerKathe FoxIsaac S. KohaneKatherine P. LiaoKun-Hsing YuS. C. KouNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 5, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Feicheng Wang Shihao Yang Nathan Palmer Kathe Fox Isaac S. Kohane Katherine P. Liao Kun-Hsing Yu S. C. Kou Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
description	Abstract Immune checkpoint inhibitors have demonstrated significant survival benefits in treating many types of cancers. However, their immune-related adverse events (irAEs) have not been systematically evaluated across cancer types in large-scale real-world populations. To address this gap, we conducted real-world data analyses using nationwide insurance claims data with 85.97 million enrollees across 8 years. We identified a significantly increased risk of developing irAEs among patients receiving immunotherapy agents in all seven cancer types commonly treated with immune checkpoint inhibitors. By six months after treatment initialization, those receiving immunotherapy were 1.50–4.00 times (95% CI, lower bound from 1.15 to 2.16, upper bound from 1.69 to 20.36) more likely to develop irAEs in the first 6 months of treatment, compared to matched chemotherapy or targeted therapy groups, with a total of 92,858 patients. The risk of developing irAEs among patients using nivolumab is higher compared to those using pembrolizumab. These results confirmed the need for clinicians to assess irAEs among cancer patients undergoing immunotherapy as part of management. Our methods are extensible to characterizing the effectiveness and adverse effects of novel treatments in large populations in an efficient and economical fashion.
format	article
author	Feicheng Wang Shihao Yang Nathan Palmer Kathe Fox Isaac S. Kohane Katherine P. Liao Kun-Hsing Yu S. C. Kou
author_facet	Feicheng Wang Shihao Yang Nathan Palmer Kathe Fox Isaac S. Kohane Katherine P. Liao Kun-Hsing Yu S. C. Kou
author_sort	Feicheng Wang
title	Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
title_short	Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
title_full	Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
title_fullStr	Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
title_full_unstemmed	Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
title_sort	real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c77b8b4112604201bb4324a10379722d
work_keys_str_mv	AT feichengwang realworlddataanalysesunveiledtheimmunerelatedadverseeffectsofimmunecheckpointinhibitorsacrosscancertypes AT shihaoyang realworlddataanalysesunveiledtheimmunerelatedadverseeffectsofimmunecheckpointinhibitorsacrosscancertypes AT nathanpalmer realworlddataanalysesunveiledtheimmunerelatedadverseeffectsofimmunecheckpointinhibitorsacrosscancertypes AT kathefox realworlddataanalysesunveiledtheimmunerelatedadverseeffectsofimmunecheckpointinhibitorsacrosscancertypes AT isaacskohane realworlddataanalysesunveiledtheimmunerelatedadverseeffectsofimmunecheckpointinhibitorsacrosscancertypes AT katherinepliao realworlddataanalysesunveiledtheimmunerelatedadverseeffectsofimmunecheckpointinhibitorsacrosscancertypes AT kunhsingyu realworlddataanalysesunveiledtheimmunerelatedadverseeffectsofimmunecheckpointinhibitorsacrosscancertypes AT sckou realworlddataanalysesunveiledtheimmunerelatedadverseeffectsofimmunecheckpointinhibitorsacrosscancertypes
_version_	1718376995861037056

Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types

Ejemplares similares